VSee Health 
The delisting determination was triggered under Nasdaq Rule 5810(c)(3)(A)(iii), which activates when a company's shares trade at or below $0.10 for 10 consecutive business days. VSEE had been hovering just above that threshold in mid-July 2026 before falling sharply. At the time of the Aug 5 trading session, Vantafin live quote data showed VSEE at $0.06, down 45.45% for the session, with volume exceeding 11.4 million shares.
What triggered the delisting determination
VSee Health filed an 8-K with the Securities and Exchange Commission on August 4, 2026, disclosing the Staff Delisting Determination from Nasdaq. The rule cited, 5810(c)(3)(A)(iii), is part of Nasdaq's minimum bid price compliance framework and does not require prior notice beyond the compliance extension already in place.
The company had previously operated under a compliance extension set to expire in September 2026, and had been exploring reverse stock split proposals alongside recent LOI announcements as part of its efforts to address the sustained low-share-price situation.
VSEE closed at $0.11 on June 24, 2026, and declined steadily through July, briefly touching $0.1055 on July 15 before falling to $0.062 by August 5. The chart below shows the sharp downward trajectory over the prior six weeks.
Can VSee Health appeal
The company has until August 6, 2026 to request a hearing before a Nasdaq Listing Qualifications Hearings Panel. Filing a request does not automatically stay the suspension of trading. The outcome of a hearing depends on whether the panel finds a basis for exception, which typically requires demonstrated ability to regain and maintain compliance within a defined period.
What comes next for VSEE shareholders
If delisting proceeds as scheduled, VSee Health shares are expected to begin trading on the OTC Markets platform. OTC trading carries distinct characteristics: reduced liquidity, wider bid-ask spreads, and no eligibility for inclusion in major market indices. For current shareholders, this transition may affect the ability to sell shares at preferred prices and could limit institutional ownership.
Vantafin's Market Insights topic hub tracks delisting events, compliance developments, and broader market data for Nasdaq and OTC-listed healthcare companies.
VSee Health fundamentals at a glance
VSee Health is a telehealth care solutions provider headquartered in Newton, Massachusetts, led by CEO Milton Chen. Its iDoc Telehealth platform serves neurointensive care, cardiac ICU, and intensive care units. The company reported $14.62M in revenue for fiscal year 2025, a 40% increase over the prior year, but posted a net loss of $14.71M and an operating loss of $9.58M. Vantafin's VSEE financials page has the full income statement history.
The company had previously regained compliance with Nasdaq's stockholders' equity requirement in December 2025, demonstrating that compliance challenges are not new for VSEE. Its next scheduled earnings release is September 28, 2026, with consensus estimates calling for EPS of -$0.06 and revenue of $5.20M.
Short interest data from Vantafin shows 1,647,591 shares sold short as of mid-July 2026, with days-to-cover at approximately 1.0 day against an average daily volume of 3.8 million shares.
Investors monitoring VSEE can use Vantafin's quote page for live price updates, the VSEE financials page for income statement history, and the screener tool to compare healthcare sector performance during periods of delisting risk.